一品红(300723.SZ)：子公司馥感啉颗粒获得药物临床试验通知书

Core Viewpoint - Yipinhong Pharmaceutical (300723.SZ) has received approval from the National Medical Products Administration for clinical trials of its Fuganlin granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1 - Yipinhong Pharmaceutical's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the development of Fuganlin granules [1] - The clinical trial approval indicates a significant step forward in the company's product pipeline and potential market expansion [1]